MV-NIS, an oncolytic measles virus derived from a live attenuated vaccine strain encoding human thyroidal sodium iodine symporter (NIS), entered clinical trials for application in several malignancies including multiple myeloma [176] and ovarian cancer [177]. This evidence concerns the gene SLC5A5 and plasma cell myeloma.